Everything below concerns Preclinical research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-20. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
== Prevention == The first control method is preventive and aims to eradicate the adult flies before they can cause any damage. The second control method is treatment once the infestation is present, and concerns the infected animals (including humans). The principal control method of adult populations of myiasis-inducing flies involves insecticide applications in the environment where the target livestock is kept. Organophosphorus or organochlorine compounds may be used, usually in a spraying formulation. One alternative prevention method is the sterile insect technique (SIT) where a significant number of artificially reared sterilized (usually through irradiation) male flies are introduced. The male flies compete with wild breed males for females to copulate and thus cause females to lay batches of unfertilized eggs that cannot develop into the larval stage. One prevention method involves removing the environment most favourable to the flies, such as by removal of the tail. Another example is the crutching of sheep, which involves the removal of wool from around the tail and between the rear legs, which is a favourable environment for the larvae. Another, more permanent, practice that is used in some countries is mulesing, where the skin is removed from young animals to tighten remaining skin – leaving it less prone to fly attack. To prevent myiasis in humans, there is a need for general improvement of sanitation, personal hygiene, and extermination of the flies by insecticides.
European Commission Regulation (EC) No 2073/2005 of November 15, 2005 European Committee for Standardization (CEN): Standard method for the detection of norovirus and hepatitis A virus in food products (shellfish, fruits and vegetables, surfaces and bottled water) CODEX Committee on Food Hygiene (CCFH): Guideline for the application of general principles of food hygiene for the control of viruses in food
=== 2025–present: Later work === Freeman returned to the heist franchise acting in Now You See Me: Now You Don't which was released in November 2025. It marks his first theatrical release in several years. Speaking about the possibility of retiring, Freeman said: "Sometimes the idea of retirement would float past me but, as soon as my agent says there's a job or somebody wants you or they've made an offer, the whole thing just boils back into where it was yesterday. 'how much you're going to pay, where we’re gonna be?' The appetite is still there. I will concede that it's dimmed a little. But not enough to make a serious difference."
Sources: en.wikipedia.org
== Awards and distinctions == 2025: Chevalier, Ordre national de la Légion d'honneur 2025: Engaged for the ocean award of Fondation de la mer 2024: Fellow, Association for the Sciences of Limnology and Oceanography 2023, Elected foreign member, Chinese Academy of Sciences 2020, Ruth Patrick Award, Association for the Sciences of Limnology and Oceanography 2018, Elected member, Academia Europaea 2014, Blaise Pascal Medal in Earth and Environmental Sciences, and elected member of the European Academy of Sciences 2012, Vladimir Vernadsky Medal, European Geosciences Union 2005, Union Service Award, European Geosciences Union 2002, Outstanding reviewer, Limnology & Oceanography 2001, Oceanography medal, Société d'océanographie de France
== Personal life == In 1963, Horváth married Valeria Scioscioli in Rome, and they emigrated to the United States. He joined the Physics Research Laboratory at Harvard Medical School. The couple had two daughters.
The raid failed, and the dissidents and mercenaries were killed or captured. The owner of Silvercorp, an ex-US special operations sergeant, said he met with Trump administration officials about the plan. Absent any vote tallies, Maduro was declared the winner of the 2024 Venezuelan presidential election by the government-controlled National Electoral Council; the result was "widely condemned as fraudulent by international observers and the opposition" who found statistical improbabilities in the results. The opposition showed evidence and vote tallies that its candidate, Edmundo González, had won a majority, matching the results of pre-election opinion polls, who was "widely believed to have won [the] election, and by a landslide", according to The New York Times. The Venezuelan government issued an arrest warrant for González, who left the country and was granted asylum in Spain. In January 2025, the Biden administration recognized González as Venezuela's legitimate president-elect. The Trump administration had sought to prosecute Maduro on narco-terrorism charges since at least 2020. At a 2023 press conference, Trump said, "Venezuela was about to collapse. We would have taken over it... [and] kept all that oil."
=== Photobiont === The photobiont partner of Parmotrema perlatum is from Trebouxia, a green algal genus belonging to the order Trebouxiales (order Chlorophyta). It has been identified as an undescribed species within a clade containing Trebouxia arboricola. A study compared the desiccation tolerance and physiological responses of lichenised Trebouxia to isolated cultures of the same alga. Both forms can survive extended desiccation, but with differing responses to photo-oxidative stress. Lichenisation enhances the photoprotective mechanisms of Trebouxia, improving quenching of excess light energy, particularly under high relative humidity, and controlling reactive oxygen species production under light exposure. However, isolated cultures showed better photosynthetic performance after desiccation recovery. This research demonstrates the mutual benefits of the lichen-photobiont partnership, where the alga gains a sheltered environment boosting its resilience to environmental stressors. Further studies on Parmotrema perlatum revealed specific antioxidant mechanisms supporting its photobiont under stress. The lichen shows high levels of reactive oxygen species scavenging enzymes such as superoxide dismutase and ascorbate peroxidase, protecting the photobiont from oxidative damage during dehydration and rehydration cycles. This enhanced antioxidant system provides not only physical shelter but also biochemical protection, increasing the photobiont's resilience to environmental fluctuations.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.